Radiation plus endostatin and capecitabine for nasopharyngeal cancer
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This Phase 2 trial tests whether adding endostatin and capecitabine to standard radiation can improve outcomes for people with non-keratinizing nasopharyngeal cancer that has not responded well to chemotherapy. It may help those with stable or worsening disease after treatment before moving to radiation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have non-keratinizing nasopharyngeal cancer confirmed by pathology (not keratinizing or basaloid type).
- Your cancer stage is T3–4 and involves lymph nodes on the same or different side (N1/N2/N3), with no spread to distant organs (M0).
- You received neoadjuvant chemotherapy (NACT) first, and scans showed stable or progressive disease—not a complete or partial response.
- Your overall health is good enough (Karnofsky score above 70).
- Your blood counts, liver labs, and kidney function are within required ranges.
- You can’t be pregnant or breastfeeding, and you must not have had prior radiation or prior chemotherapy/surgery to the main tumor or involved lymph nodes.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of a new immunotherapy (envafolimab) with standard chemoradiation and a drug that blocks blood vessel growth (endostatin) for people with advanced nasopharyngeal cancer that hasn't been treated before. The goal is to see if this combination works better than the usual treatment.
This trial tests whether adding the immunotherapy drug toripalimab to the chemotherapy pill capecitabine after standard treatment helps prevent nasopharyngeal cancer from coming back. It is for people with high-risk features who have already had chemo and radiation.
This trial tests whether taking the chemo tablet capecitabine after standard chemoradiation can help prevent cancer from coming back, and whether adding an immune therapy (a PD-1 antibody) improves results. It is for people with high-risk nasopharyngeal (throat) cancer whose main treatment has already finished.
This Phase 3 trial studies whether adding low-dose radiation to cadonilimab (an immune therapy) can improve outcomes for people newly diagnosed with a specific type and stage of nasopharyngeal cancer. If you’re eligible, it may offer a new treatment approach and helps researchers confirm whether it works best.
This trial tests a combination of chemotherapy (three drugs: docetaxel, cisplatin, and fluorouracil) plus an immunotherapy drug (a PD-1 inhibitor, which helps your immune system fight cancer) given before the standard radiation treatment for nasopharyngeal cancer. The goal is to see if this upfront treatment can improve outcomes in patients whose cancer has not spread to distant parts of the body.
This trial tests combining induction chemotherapy and immunotherapy with radiation, with or without additional chemotherapy, for patients with advanced nasopharyngeal cancer (throat cancer). It aims to see if adding chemotherapy during radiation improves outcomes compared to not having it.
Hear when a new Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.